[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cytotoxicity\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cytotoxicity":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,39,64,88,112,147],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100644496","biological-evaluation-of-orthopedic-materials-an-in-vitro-study-using-patient-derived-human-samples-100644496",false,"NCT07671521","Biological Evaluation of Orthopedic Materials: An In Vitro Study Using Patient-Derived Human Samples","RAISE","Femoral condyle, tibial plateau and synovial membrane samples\n\nPatients undergoing primary total knee arthroplasty at the Orthopaedic and Trauma Clinic II of the IRCCS Istituto Ortopedico Rizzoli (Bologna, Italy), in whom collection of tibial plateau, femoral condyles and\u002For synovial tissue is planned.\n\nInclusion criteria:\n\nAge 18-80 years, male or female Primary tricompartmental osteoarthritis Body Mass Index (BMI) \\\u003C 35 Kellgren-Lawrence grade III-IV osteoarthritis Written informed consent\n\nExclusion criteria:\n\nPrevious partial knee arthroplasty or cartilage repair\u002Fregenerative procedures Rheumatoid arthritis or chronic corticosteroid\u002Fimmunosuppressive therapy Positive testing for HIV, HBV or HCV infection Concentrated bone marrow (BMC) samples\n\nPatients of both sexes providing written informed consent and presenting with the following characteristics:\n\nInclusion criteria:\n\nAge 18-70 years Medial compartment knee osteoarthritis (Kellgren-Lawrence grade II-III for \\>4 months) Failure of ≥6 months of conservative treatment (NSAIDs\u002Fanalgesics, hyaluronic acid, corticosteroid or PRP injections) Written informed consent\n\nExclusion criteria:\n\nInability to provide informed consent Knee trauma within the previous 6 months Malignancy, rheumatic disease, uncontrolled diabetes, uncontrolled thyroid disorders Alcohol or drug abuse BMI \\> 35 Intra-articular injections within the previous 6 months Knee surgery within the previous 12 months HIV, HBV or HCV positivity Platelet-rich plasma (PRP) samples\n\nPatients of both sexes with degenerative cartilage disease of the knee.\n\nInclusion criteria:\n\nAge 18-65 years Clinical signs and symptoms of knee cartilage degeneration Radiographic or MRI evidence of degeneration (Kellgren-Lawrence grade II-IV) Hemoglobin \\> 11 g\u002FdL Platelet count \\> 150,000\u002Fmm³ No clinically relevant ECG abnormalities Written informed consent\n\nExclusion criteria:\n\nRheumatoid arthritis or chronic corticosteroid\u002Fimmunosuppressive therapy Uncontrolled diabetes Hematological disorders or anticoagulant\u002Fantiplatelet therapy Thyroid metabolic disorders Alcohol, drug or medication abuse NSAID use within 3 days prior to blood draw Cardiovascular disease contraindicating a 150 mL blood draw HIV, HBV or HCV positivity","ALL","18 Years","80 Years",{"count":20,"type":21},50,"ESTIMATED","OBSERVATIONAL","The anterior cruciate ligament (ACL) is the primary stabilizer of the knee joint, and ACL injuries are highly prevalent, particularly among physically active and athletic individuals. Although ACL reconstruction is a well-established orthopedic procedure, significant challenges remain regarding biological integration between the graft and bone, which may negatively affect clinical outcomes.\n\nIn recent years, advanced biomaterials and regenerative medicine approaches have gained increasing attention as potential strategies to enhance osteointegration and promote more physiological tissue healing. Before clinical application, these materials must undergo rigorous in vitro biological evaluation in accordance with international standards, particularly ISO 10993-5 for cytotoxicity assessment.\n\nThe study will investigate cytotoxicity, cell viability, inflammatory responses, pro-fibrotic effects, and osteogenic potential using relevant human cell models. The regenerative effects of platelet-rich plasma (PRP), a source of growth factors, will also be evaluated.\n\nThe biomaterials under investigation include a titanium alloy and polylactic acid (PLA), both widely used in orthopedic applications. The main objective is to demonstrate their biocompatibility, absence of cytotoxic, inflammatory, and pro-fibrotic effects, and their ability to support osteogenic processes and tissue integration. The findings will provide essential evidence for subsequent preclinical in vivo studies and future clinical translation.",[25],"Cytotoxicity","NOT_YET_RECRUITING","2026-06-22",{"date":29,"type":30},"2026-06-26","ACTUAL",{"date":32,"type":21},"2026-07",{"date":34,"type":21},"2028-06",{"name":36,"class":37},"Stefano Zaffagnini","OTHER",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":46,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":49,"conditions":50,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":4},"100644024","effects-of-chlorhexidine-on-human-gingival-fibroblasts-100644024","NCT07669636","Effects of Chlorhexidine on Human Gingival Fibroblasts","In Vitro Effects of a New Chlorhexidine-based Solution on Human Gingival Fibroblasts Survival and Function","Inclusion Criteria:\n\n* Male or female adults aged 18 years or older.\n* Undergoing routine dental surgical procedures (e.g., tooth extraction or gingivectomy).\n* Willing and able to provide written informed consent for the use of discarded gingival tissue for research purposes.\n* Systemically healthy.\n\nExclusion Criteria:\n\n* Presence of systemic diseases.\n* Presence of relevant medical comorbidities.\n* Current smoker.\n* Refusal to provide informed consent for the use of discarded biological material.",true,{"count":48,"type":21},3,"This prospective in vitro study aims to evaluate the effects of two chlorhexidine-based mouthwash formulations on the survival and function of human gingival fibroblasts (hGFs). Gingival fibroblasts obtained from discarded gingival tissue collected during routine dental procedures will be cultured and exposed to different concentrations of a conventional 0.2% chlorhexidine mouthwash and a 0.2% chlorhexidine mouthwash supplemented with N-acetylcysteine (NAC) and hyaluronic acid (HA).\n\nCell viability, apoptosis, migration, and gene expression will be assessed at multiple time points using Trypan Blue exclusion assay, fluorescence-activated cell sorting (FACS), scratch assay, and quantitative real-time PCR. The study is designed to investigate the concentration-dependent effects of chlorhexidine on fibroblast viability and wound-healing-related functions and to determine whether the addition of NAC and HA may improve the biological compatibility of chlorhexidine-based formulations.",[51,52,53,25,54],"HGF","Fibroblast","Chlorhexidine","Biocompatibility","2026-06-20",{"date":57,"type":30},"2026-06-25",{"date":59,"type":21},"2026-07-01",{"date":61,"type":21},"2026-11-01",{"name":63,"class":37},"IRCCS San Raffaele",{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":4,"eligibilityCriteria":70,"healthyVolunteers":46,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":71,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":73,"conditions":74,"keywords":75,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":38},"100622248","in-vitro-cytotoxicity-assessment-of-inox-nanoksa-g-plus-polymer-discs-100622248","NCT07381153","In-Vitro Cytotoxicity Assessment of INOX (Nanoksa G Plus) Polymer Discs","Cytotoxicity Evaluation of INOX (Nanoksa G Plus) High-Performance Polymer Discs on Cell Cultures: An In-Vitro Experimental Study","Inclusion Criteria:\n\nTo assess cell viability following exposure to INOX material extracts using a quantitative cell viability assay.\n\nExclusion Criteria:\n\nTo evaluate cell membrane integrity following exposure to INOX extracts. To assess cellular morphology after exposure to the material. To compare cytotoxic effects at different extract concentrations. To determine whether INOX meets accepted non-cytotoxicity thresholds.",{"count":72,"type":21},20,"This study aims to evaluate the cytotoxicity of INOX (Nanoksa G Plus) high-performance polymer discs on cell cultures using standardized in-vitro assays. The primary objective is to assess cell viability after exposure to INOX extracts. Secondary objectives include examining cell membrane integrity, cellular morphology, comparing effects across extract concentrations, and determining whether INOX meets accepted non-cytotoxicity standards.",[25],[76,77,78],"INOX","Nanoksa G Plus","INVITRO","2026-03-17",{"date":81,"type":30},"2026-03-19",{"date":83,"type":21},"2027-01-20",{"date":85,"type":21},"2027-01-30",{"name":87,"class":37},"Cairo University",{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":4,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":95,"targetDuration":4,"studyType":97,"phases":98,"briefSummary":100,"conditions":101,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":4},"100575423","probiotic-supplementation-during-cytotoxic-chemotherapy-for-solid-tumor-malignancies-100575423","NCT06772090","Probiotic Supplementation During Cytotoxic Chemotherapy for Solid Tumor Malignancies","A Randomized Placebo-controlled Feasibility Trial of Probiotic Supplementation During Adjuvant or Neoadjuvant Cytotoxic Chemotherapy for Solid Tumor Malignancies","Inclusion Criteria:\n\n* Adults ≥18 years old\n* Diagnosis of stage III colon cancer\n* Undergoing chemotherapeutic treatment within the MHFV or MVAHC medical systems.\n\nExclusion Criteria:\n\n* Allergy or sensitivity to probiotic supplementation\n* Diagnosis\u002Fhistory of:\n\nNon-colon GI cancer or chronic GI-related disease or disorders such as gastric ulcer, irritable bowel syndrome, inflammatory bowel disease, or intestinal malabsorption syndrome Cognitive impairment, such as dementia, or developmental disorder that would affect ability to give consent or comply with study procedures\n\n* Current treatment of cancer other than non-melanoma skin cancer, including metastases and recurrences\n* Current participation in another interventional study of medication(s)\n* Major changes in eating habits within the past 3 months, such as stopping or starting a restricted diet\n* BMI ≥40 kg\u002Fm2 or ≤17 kg\u002Fm2\n* Unexpected change in weight of ˃4.5 kg within the past 6 months",{"count":96,"type":21},40,"INTERVENTIONAL",[99],"NA","This is a pilot single-blind placebo-controlled randomized trial to establish experimental feasibility. We plan on enrolling a pilot cohort of 40 patients, with up to 5 patients in treatment phase 0 and the remaining in treatment phase I. During Phase I, the remaining participants will be assigned to either treatment or control group using dynamic block randomization balancing on sex, age group, and disease histology.",[102,25],"Solid Tumor, Adult","2026-02-02",{"date":105,"type":30},"2026-02-03",{"date":107,"type":21},"2026-12-25",{"date":109,"type":21},"2028-12-31",{"name":111,"class":37},"Masonic Cancer Center, University of Minnesota",{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":119,"enrollmentInfo":120,"targetDuration":4,"studyType":97,"phases":122,"briefSummary":125,"conditions":126,"keywords":130,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":4},"100406709","phase-2-anticariogenic-effect-of-moringa-oleifera-mouthwash-compared-to-chlorhexidine-mouthwash-100406709","NCT04575948","Anticariogenic Effect of Moringa Oleifera Mouthwash Compared to Chlorhexidine Mouthwash","Antibacterial, Antiplaque and Anticariogenic Effect of Moringa Oleifera Mouthwash Compared to Chlorhexidine Mouthwash: A Randomized Clinical Trial","Inclusion Criteria:\n\n* Systemically free as reported by the patients\n* Minimum of 20 teeth present in the dentition (excluding wisdom teeth);\n* Clinically healthy gingiva (on intact periodontium)\n* Dental biofilm-induced gingivitis (plaque induced gingivitis) according to the criteria set by the American Academy of Periodontology for classification of periodontal diseases and conditions in 2017\n* Moderate to high caries risk patients\n\nExclusion Criteria:\n\n* Patients with periodontitis or requiring other immediate dental treatments (within the current 6 months)\n* Subjects on antibiotics within last 6 months\n* Periodontal therapy for the past 6 months\n* Pregnant women and lactating mothers\n* Medically compromised patients\n* Subjects with tobacco consumption in any form\n* Subjects wearing partial dentures or having clinically unacceptable restorations or bridges\n* Subjects wearing orthodontic appliances\n* History of allergy to chemical or any herbal products","50 Years",{"count":121,"type":21},90,[123,124],"PHASE2","PHASE3","Moringa oleifera (MO) is an extraordinary nutritious vegetable tree with high medicinal value for its antibacterial properties. Formulation of various natural dental remedies from this plant and their testing for their effectiveness might yield promising antibacterial, antiplaque and anticariogenic agents with minimal side effects.\n\nAim of the study:\n\nPart I: The aim of this in-vitro part of the study is to formulate a nontoxic mouthwash from MO leaves extract, having antimicrobial activity, to be used in part II of the study. Furthermore, stability and efficacy of the developed mouth wash will be evaluated.\n\nPart II: The aim of this randomized controlled trial is to evaluate the antibacterial, antiplaque and anticariogenic effect of MO mouthwash compared to chlorhexidine mouthwash.",[127,128,129,25],"Plaque, Dental","Antimicrobial","Mouthwash",[131,132,133,134,135,136,137],"Moringa Oleifera","antibacterial activity","mouthwash","chlorhexidine","antiplaque","herbal","translational research","2026-01-26",{"date":140,"type":30},"2026-01-27",{"date":142,"type":21},"2027-12",{"date":144,"type":21},"2028-12",{"name":146,"class":37},"Misr International University",{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":4,"eligibilityCriteria":153,"healthyVolunteers":46,"sex":16,"minAge":154,"maxAge":155,"enrollmentInfo":156,"targetDuration":4,"studyType":97,"phases":158,"briefSummary":160,"conditions":161,"keywords":163,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":38},"100554741","phase-4-evaluate-cytotoxicity-leaching-and-structural-conformation-of-clear-aligners-100554741","NCT06503029","Evaluate Cytotoxicity, Leaching, and Structural Conformation of Clear Aligners","Cytotoxicity, Leaching, and Structural Conformation of Invisalign Clear Aligners Subjected to Different Cleaning Methods: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Participants who are on Invisalign Clear aligner treatment.\n* Participants who are 21 years and older and committed to their treatment.\n* Participants with caries-free dentition\n* Participants with no smoking habits\n* Participants are not pregnant females\n\nExclusion Criteria:\n\n* Participants who are on Orthognathic treatment.\n* Participants with Hypodontia.","21 Years","40 Years",{"count":157,"type":21},84,[159],"PHASE4","The aim is to evaluate clear aligners' cytotoxicity, leaching, and structural properties and compare them with four cleaning tools. The null hypothesis is the cleansers have no impact on the properties tested.",[162,25],"Malocclusion",[25,164,165,166],"Leaching","Clear aligner","Orthodontics","2024-07-09",{"date":169,"type":30},"2024-07-16",{"date":171,"type":21},"2024-07-15",{"date":173,"type":21},"2025-03-05",{"name":175,"class":37},"Riyadh Elm University"]